Search

Real-world data announced for adults with type 2 diabetes

Two analyses of the U.S. data from the EMPRISE real-world study show that Jardiance (empagliflozin) tablets was associated with a reduction in risk of hospitalization for heart failure compared with two other classes of glucose-lowering therapies in adult

U.S. FDA Accepts New Drug Application for Triple Combination Tablet for Adults with Type 2 Diabetes

Biosimilar Candidate to Humira® Accepted For Review | BI US

Boehringer Ingelheim announced today that its adalimumab biosimilar candidate to Humira®, has been accepted for regulatory review by the EMA and the FDA.

Boehringer Ingelheim unveils groundbreaking Research and Development space in St. Joseph, Mo.

Clinical Development and Operations

Click here to find out more on how Boehringer Ingelheim is proud to offer a new 2-year Fellowship program within Clinical Operations.

Cyltezo® (adalimumab-adbm) Patent Litigation Resolution| BI US

Read more about Boehringer Ingelheim's CYLTEZO patent litigation resolution, meaning greater access to the treatment for patients across the USA.

Our Environment

The View from Both Sides of the Table

FDA accepts Jardiance sNDA for T2D in children 10 and older

The US FDA has accepted a supplemental New Drug Application for Jardiance® (empagliflozin) tablets as a potential treatment for children 10 years and older with type 2 diabetes

Ivermectin in Animal Health products and COVID-19

Investigating MDM2-p53 in cancer

Our most advanced oncology asset in development is being clinically investigated as a potential treatment for people with dedifferentiated liposarcoma.

Sophia Malki: A Woman on the Rise

Xochimilco

With its presence in Greece of more than a half century,

Ingelheim

The company headquarters of Boehringer Ingelheim are located in Ingelheim, Germany.

Leadership insights about our focus on patient centricity

Read about our patient-centric approach in discovering and developing medicines that transform patients’ lives from the point of view of Keri Yale, our head of patient centricity and engagement

MERIAL: RECOMBITEK® Oral Bordetella Vaccine | Boehringer Ingelheim US

MERIAL, now part of Boehringer Ingelheim, grows canine vaccine portfolio with the introduction of the RECOMBITEK® Oral Bordetella vaccine.

Boehringer Ingelheim Vetmedica, Inc. to Establish North America and U.S. Headquarters in Duluth, Ga. Following Close of BI/Sanofi Asset Swap

Boehringer Ingelheim Statement: Favorable Ruling on Humira® Patent Challenge from U.S. Patent and Trademark Office

Our Commitment

Combating counterfeits requires a globally-coordinated effort of all public and private stakeholders affected. On a corporate basis and locally we actively support those initiatives by associations, law-enforcement authorities and governments. These are d

Vampire Bats & Rabies: A Potential New Threat | Boehringer Ingelheim US

Read more on the emerging threat of rabid vampire bats in the Southern US. Helping prevent this disease preserves the lives of livestock worldwide.

Expanded Access Programs

Foot-and-Mouth-Disease Quick Response | Boehringer Ingelheim US

Click here to read more on Boehringer Ingelheim's fight against foot-and-mouth disease (FMD), with our experts able to contain an outbreak in just six days.

Our Work with the Gates Foundation | COVID-19 | Boehringer Ingelheim US

With global life science companies, we are joining the COVID-19 Therapeutics Accelerator of the Bill & Melinda Gates Foundation to fight the pandemic.

Boehringer Ingelheim and Vanderbilt University join forces to develop new Ras inhibitors for cancer treatment

Boehringer Ingelheim and Vanderbilt University join forces

Boehringer Ingelheim Completes Plant Expansion After $76 Million Georgia Investment

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers